路透社9月25日 - 美国食品和药物管理局周四批准了Crinetics PharmaceuticalsCRNX.O公司治疗一种罕见荷尔蒙失调症的药物，使其成为该国第一种每日一次的口服药物。
这种罕见的疾病是脑垂体分泌过多的生长激素，导致骨骼、器官和其他组织变大。这是由于脑垂体上的肿瘤引起的。
根据美国国立卫生研究院的数据，科学家估计每 10 万人中就有 3 到 14 人被诊断出患有肢端肥大症。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.